Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue
- PMID: 12531881
- PMCID: PMC151880
- DOI: 10.1172/JCI17193
Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue
Abstract
Current therapeutic strategies for genetic skin disorders rely on the complex process of grafting genetically engineered tissue to recipient wound beds. Because fibroblasts synthesize and secrete extracellular matrix, we explored their utility in recessive dystrophic epidermolysis bullosa (RDEB), a blistering disease due to defective extracellular type VII collagen. Intradermal injection of RDEB fibroblasts overexpressing type VII collagen into intact RDEB skin stably restored correctly localized type VII collagen expression in vivo and normalized hallmark RDEB disease features, including subepidermal blistering and anchoring fibril defects. This article was published online in advance of the print edition. The date of publication is available from the JCI website, http://www.jci.org.
Figures
References
-
- Chen M, et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat. Genet. 2002;32:670–675. - PubMed
-
- Ortiz-Urda S, et al. Stable nonviral genetic correction of inherited human skin disease. Nat. Med. 2002;8:1166–1170. - PubMed
-
- Petersen MJ, et al. Sustained production of human transferrin by transduced fibroblasts implanted into athymic mice: a model for somatic gene therapy. J. Invest. Dermatol. 1995;104:171–176. - PubMed
-
- Garver RI, Jr, Chytil A, Courtney M, Crystal RG. Clonal gene therapy: in vivo expression of a transplanted monoclonal population of murine fibroblasts containing a retrovirus inserted human alpha 1-antitrypsin gene. Trans. Assoc. Am. Physicians. 1987;100:10–20. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
